Pictet Asset Management
RYTM icon

Pictet Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Pictet Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106M Buy
957,785
+290,739
+44% +$26.3M 0.1% 215
2026
Q1 		$57.3M Buy
667,046
+52,383
+9% +$5.09M 0.06% 288
2025
Q4 		$66.2M Sell
614,663
-68,354
-10% -$7.25M 0.06% 281
2025
Q3 		$69M Buy
683,017
+266,902
+64% +$24.8M 0.07% 263
2025
Q2 		$26.3M Buy
416,115
+156,769
+60% +$9.6M 0.03% 441
2025
Q1 		$13.9M Sell
259,346
-116,003
-31% -$6.44M 0.02% 577
2024
Q4 		$21M Buy
375,349
+46,010
+14% +$2.54M 0.02% 489
2024
Q3 		$17.3M Sell
329,339
-472,457
-59% -$22.6M 0.02% 529
2024
Q2 		$32.9M Sell
801,796
-409,883
-34% -$16.4M 0.04% 356
2024
Q1 		$52.5M Buy
1,211,679
+47,718
+4% +$2.09M 0.06% 302
2023
Q4 		$53.5M Buy
+1,163,961
New +$36.7M 0.06% 291

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pictet Asset Management's RYTM Position: Q2 2026 in Review

Pictet Asset Management increased its Rhythm Pharmaceuticals (RYTM) stake by 44% in Q2 2026, buying an estimated $26.3M and bringing the position to 957,785 shares worth $106M. The position accounts for 0.1% of the portfolio, ranked #215.

Pictet Asset Management first reported a position in RYTM in Q4 2023 and has held it in 11 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Pictet Asset Management held 957,785 shares of Rhythm Pharmaceuticals worth $106M as of Q2 2026.
  • Pictet Asset Management bought 290,739 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $26.3M.
  • Rhythm Pharmaceuticals made up 0.1% of Pictet Asset Management's portfolio in Q2 2026, its #215 holding.
  • Pictet Asset Management first reported a position in Rhythm Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.